Quality of Recovery After Reversal With Neostigmine or Sugammadex.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-30

Study Completion Date

2018-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will compare patient recovery measures after reversal of neuromuscular blockade with neostigmine or sugammadex after surgery. Measures include pulmonary function, muscle strength, time to extubation and quality of recovery in the post anesthesia care unit.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Randomized Double Blind Controlled Trial Comparing Sugammadex and Neostigmine After Thoracic Anesthesia

NCT02256280

Neuromuscular Blockade

TERMINATED PHASE4

Effects of Neuromuscular Block Reversal With Sugammadex vs Neostigmine on Postoperative Respiratory Outcomes After Major Abdominal Surgery

NCT02361060

Major Abdominal Surgery

COMPLETED PHASE4

Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium

NCT03328312

Incidence of Postoperative Residual Curarization

UNKNOWN EARLY_PHASE1

Sugammadex vs Placebo to Prevent Residual Neuromuscular Block

NCT02728726

General Surgery

COMPLETED PHASE4

Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028)

NCT00559468

Anesthesia, General

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sugammadex has been shown to have a faster onset and more reliable reversal of neuromuscular blockade when compared to neostigmine as measured by return of Train-of-four (TOF) ratio to \>0.9. (Breuckmann, 2015) The investigator's hypothesis is that sugammadex will be associated with improved deep breathing as measured by incentive spirometry in the PACU. The investigators also hypothesize that patients reversed with sugammadex will have shorter times to extubation and better recovery profiles in the PACU as measured by strength, PACU discharge readiness and quality of recovery scores.

Residual neuromuscular blockade after surgery can result in airway compromise, pulmonary complications, and possible need for reintubation and can be a negative experience for patients. Reintubation after surgery is currently a quality measure in NSQIP (National Surgery Quality Improvement Program) A TOF ratio of \<0.9 has been identified as a marker of residual neuromuscular blockade in the PACU. (Farhan 2013) Several clinical trials have shown that reversal of neuromuscular blockade with sugammadex results in a faster and more reliable return to TOF ratio of \>0.9 when compared to neostigmine. However most of these studies primarily report on TOF ratios. There are scant data on clinical outcomes after reversal with neostigmine versus sugammadex. Incentive spirometry is a clinically meaningful measurement of postoperative pulmonary function, i.e the ability to breath deeply, which minimizes atelectasis and risk of postoperative pneumonia.

The investigators will compare recovery profiles of patients who have received sugammadex or neostigmine for reversal of neuromuscular blockade after surgery. The primary outcome will be incentive spirometry volumes after surgery as a measure of pulmonary function. The secondary measures include hand grip measured using a dynamometer, time to extubation, time to PACU discharge, time to sit independently, and quality of recovery 15 survey scores.

This will be a single-center, prospective, randomized, assessor blinded, controlled trial. Patients will be randomized to either receive sugammadex or neostigmine for the reversal of neuromuscular blockade. The anesthesiologist will be unblinded to the study drug however the assessor in the PACU will be blinded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Incomplete Reversal of Neuromuscular Block

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neostigmine

Patients in this arm will receive neostigmine for reversal of neuromuscular blockade. Neostigmine is historically the medication that has been used for this purpose.

Group Type ACTIVE_COMPARATOR

Neostigmine

Intervention Type DRUG

Neostigmine will be given for reversal of neuromuscular blockade.

Sugammadex

Patients in this arm will receive sugammadex for reversal of neuromuscular blockade. Sugammadex is a newer, FDA approved, medication for this purpose.

Group Type ACTIVE_COMPARATOR

Sugammadex

Intervention Type DRUG

Sugammadex will be given for reversal of neuromuscular blockade.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sugammadex

Sugammadex will be given for reversal of neuromuscular blockade.

Intervention Type DRUG

Neostigmine

Neostigmine will be given for reversal of neuromuscular blockade.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bridion Prostigmine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant must be willing and able to provide written informed consent for the study
* Participant must be greater than or equal to 18 years of age
* Participant must be ASA (American Society of Anesthesiologists) class I, II or III
* Planned use of neuromuscular blocking drugs
* Planned use of endotracheal intubation
* Planned for extubation to occur in the OR

Exclusion Criteria

* ASA (American Society of Anesthesiologists) Class IV
* Age \< 18 years old
* Inability to give oral or written consent
* Known or suspected neuromuscular disorder impairing neuromuscular function
* True allergy to muscle relaxants
* A (family) history of malignant hyperthermia
* A contraindication for neostigmine or sugammadex administration
* Serum creatinine level of greater than 2.0 mg/dL
* Surgery where the patient's arm is not available for neuromuscular monitoring
* A plan to extubate under deep anesthesia
* Pregnant

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No